KFH - ANTIOCH
- Type
- Teaching hospital
- Where
- Antioch, CA
- Medicare CCN
- 050760
- Received
- $3,016,858 in 103 records, 2025 ($0 general, $3,016,858 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | Research payment | 103 | $3,016,858 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 103 | $3,016,858 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 103 | $3,016,858 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | PFIZER INC. | $57,356 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-12-30 | PFIZER INC. | $5,237 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-12-30 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST | 2025 |
| 2025-12-30 | PFIZER INC. | $573 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-12-22 | PFIZER INC. | $4,200 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | ESTABLISHING A CONTROL GROUP FOR STUDY B7471015 AMONG HOSPITALIZED PATIENTS 65 YEARS OF AGE WITHOUT INFECTIOUS DISEASE | 2025 |
| 2025-12-16 | PFIZER INC. | $865 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-12-15 | PFIZER INC. | $56,193 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | ESTABLISHING A CONTROL GROUP FOR STUDY B7471015 AMONG HOSPITALIZED PATIENTS 65 YEARS OF AGE WITHOUT INFECTIOUS DISEASE | 2025 |
| 2025-12-11 | PFIZER INC. | $11,567 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-12-04 | PFIZER INC. | $458,311 | Research payment | Cash or cash equivalent | OBSERVATIONAL COHORT STUDY EVALUATING REALWORLD ABRYSVO VACCINE EFFECTIVENESS AND IMPACT AGAINST MEDICALLYATTENDED RSVRE | 2025 | |
| 2025-11-29 | PFIZER INC. | $85,962 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-11-27 | PFIZER INC. | $3,400 | Research payment | Cash or cash equivalent | TUKYSA Drug, ONCOLOGY | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJE | 2025 |
| 2025-11-27 | PFIZER INC. | $1,282 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-11-26 | PFIZER INC. | $55,416 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRI | 2025 | |
| 2025-11-26 | PFIZER INC. | $2,036 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-11-25 | PFIZER INC. | $9,972 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-11-24 | PFIZER INC. | $56,193 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | ESTABLISHING A CONTROL GROUP FOR STUDY B7471015 AMONG HOSPITALIZED PATIENTS 65 YEARS OF AGE WITHOUT INFECTIOUS DISEASE | 2025 |
| 2025-11-12 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-11-06 | PFIZER INC. | $96 | Research payment | In-kind items and services | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2025 |
| 2025-11-06 | PFIZER INC. | $96 | Research payment | In-kind items and services | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2025 |
| 2025-11-04 | PFIZER INC. | $38,284 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-10-31 | PFIZER INC. | $10,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, ONCOLOGY | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CA | 2025 |
| 2025-10-31 | PFIZER INC. | $10,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, ONCOLOGY | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CA | 2025 |
| 2025-10-28 | PFIZER INC. | $1,790 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST | 2025 |
| 2025-10-15 | PFIZER INC. | $53,117 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-10-14 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-10-09 | PFIZER INC. | $114,577 | Research payment | Cash or cash equivalent | OBSERVATIONAL COHORT STUDY EVALUATING REALWORLD ABRYSVO VACCINE EFFECTIVENESS AND IMPACT AGAINST MEDICALLYATTENDED RSVRE | 2025 | |
| 2025-10-08 | PFIZER INC. | $3,250 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-10-07 | PFIZER INC. | $202 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2025 |
| 2025-10-03 | PFIZER INC. | $618,067 | Research payment | Cash or cash equivalent | A POSTMARKETING SAFETY STUDY TO EVALUATE THE SAFETY OF RESPIRATORY SYNCYTIAL VIRUS VACCINE ABRYSVO EXPOSURE DURING PREGN | 2025 | |
| 2025-09-25 | PFIZER INC. | $723 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST | 2025 |
| 2025-09-15 | PFIZER INC. | $10,750 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | ESTABLISHING A CONTROL GROUP FOR STUDY B7471015 AMONG HOSPITALIZED PATIENTS 65 YEARS OF AGE WITHOUT INFECTIOUS DISEASE | 2025 |
| 2025-09-12 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-09-11 | PFIZER INC. | $3,366 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2025 |
| 2025-09-11 | PFIZER INC. | $1,100 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2025 |
| 2025-09-03 | PFIZER INC. | $42,007 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-08-23 | PFIZER INC. | $4,000 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOC | 2025 | |
| 2025-08-21 | PFIZER INC. | $4,879 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2025 |
| 2025-08-20 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-08-18 | PFIZER INC. | $131,118 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | ESTABLISHING A CONTROL GROUP FOR STUDY B7471015 AMONG HOSPITALIZED PATIENTS 65 YEARS OF AGE WITHOUT INFECTIOUS DISEASE | 2025 |
| 2025-08-11 | PFIZER INC. | $302 | Research payment | Cash or cash equivalent | TUKYSA Drug, ONCOLOGY | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJE | 2025 |
| 2025-08-09 | PFIZER INC. | $47,036 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-07-30 | PFIZER INC. | $28,691 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-07-29 | PFIZER INC. | $350 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-07-18 | PFIZER INC. | $14,985 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOC | 2025 | |
| 2025-07-18 | PFIZER INC. | $14,580 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOC | 2025 | |
| 2025-07-18 | PFIZER INC. | $9,720 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOC | 2025 | |
| 2025-07-18 | PFIZER INC. | $9,315 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOC | 2025 | |
| 2025-07-11 | PFIZER INC. | $48,080 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-07-10 | PFIZER INC. | $4,166 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-07-10 | PFIZER INC. | $2,500 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-07-01 | PFIZER INC. | $32,942 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-06-28 | PFIZER INC. | $1,421 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-06-21 | PFIZER INC. | $5,584 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-06-16 | PFIZER INC. | $302 | Research payment | Cash or cash equivalent | TUKYSA Drug, ONCOLOGY | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJE | 2025 |
| 2025-06-14 | PFIZER INC. | $74,904 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-06-13 | PFIZER INC. | $1,893 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-06-12 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-05-28 | PFIZER INC. | $382,051 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | CLINICAL CHARACTERISTICS TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH HRHER2 BREAST CANCER IN THE UNITED STATES | 2025 |
| 2025-05-28 | PFIZER INC. | $14,400 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOC | 2025 | |
| 2025-05-22 | PFIZER INC. | $789 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST | 2025 |
| 2025-05-20 | PFIZER INC. | $1,666 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-05-19 | PFIZER INC. | $4,310 | Research payment | In-kind items and services | ABRYSVO Biological, VACCINES | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATOR | 2025 |
| 2025-05-19 | PFIZER INC. | $4,310 | Research payment | In-kind items and services | ABRYSVO Biological, VACCINES | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATOR | 2025 |
| 2025-05-10 | PFIZER INC. | $70,827 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-05-09 | PFIZER INC. | $2,486 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-04-25 | PFIZER INC. | $32 | Research payment | In-kind items and services | LITFULO Drug, IMMUNOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-04-15 | PFIZER INC. | $3,200 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST | 2025 |
| 2025-04-14 | PFIZER INC. | $302 | Research payment | Cash or cash equivalent | TUKYSA Drug, ONCOLOGY | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJE | 2025 |
| 2025-04-10 | PFIZER INC. | $1,873 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-04-08 | PFIZER INC. | $1,464 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2025 |
| 2025-04-07 | PFIZER INC. | $3,448 | Research payment | In-kind items and services | ABRYSVO Biological, VACCINES | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATOR | 2025 |
| 2025-04-07 | PFIZER INC. | $3,448 | Research payment | In-kind items and services | ABRYSVO Biological, VACCINES | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATOR | 2025 |
| 2025-03-29 | PFIZER INC. | $28,246 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-03-28 | PFIZER INC. | $473 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-03-26 | PFIZER INC. | $7,327 | Research payment | In-kind items and services | ABRYSVO Biological, VACCINES | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATOR | 2025 |
| 2025-03-26 | PFIZER INC. | $7,327 | Research payment | In-kind items and services | ABRYSVO Biological, VACCINES | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATOR | 2025 |
| 2025-03-11 | PFIZER INC. | $732 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2025 |
| 2025-03-06 | PFIZER INC. | $96 | Research payment | In-kind items and services | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2025 |
| 2025-03-06 | PFIZER INC. | $96 | Research payment | In-kind items and services | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2025 |
| 2025-03-04 | PFIZER INC. | $24,203 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-03-04 | PFIZER INC. | $1,873 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-03-01 | PFIZER INC. | $1,817 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-02-25 | PFIZER INC. | $936 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-02-18 | PFIZER INC. | $5,210 | Research payment | Cash or cash equivalent | TUKYSA Drug, ONCOLOGY | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJE | 2025 |
| 2025-02-18 | PFIZER INC. | $936 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-02-13 | PFIZER INC. | $10,999 | Research payment | In-kind items and services | TUKYSA Drug, ONCOLOGY | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJE | 2025 |
| 2025-02-13 | PFIZER INC. | $850 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-02-12 | PFIZER INC. | $43,996 | Research payment | In-kind items and services | TUKYSA Drug, ONCOLOGY | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJE | 2025 |
| 2025-02-11 | PFIZER INC. | $1,873 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-02-06 | PFIZER INC. | $11,938 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-02-05 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-02-04 | PFIZER INC. | $4,684 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-01-29 | PFIZER INC. | $732 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2025 |
| 2025-01-28 | PFIZER INC. | $52,759 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-01-28 | PFIZER INC. | $1,873 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-01-25 | PFIZER INC. | $2,864 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-01-22 | PFIZER INC. | $1,698 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2025 |
| 2025-01-21 | PFIZER INC. | $7,495 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-01-14 | PFIZER INC. | $2,055 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
| 2025-01-13 | PFIZER INC. | $74,925 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | ESTABLISHING A CONTROL GROUP FOR STUDY B7471015 AMONG HOSPITALIZED PATIENTS 65 YEARS OF AGE WITHOUT INFECTIOUS DISEASE | 2025 |
| 2025-01-13 | PFIZER INC. | $56,193 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | ESTABLISHING A CONTROL GROUP FOR STUDY B7471015 AMONG HOSPITALIZED PATIENTS 65 YEARS OF AGE WITHOUT INFECTIOUS DISEASE | 2025 |
| 2025-01-13 | PFIZER INC. | $7,530 | Research payment | Cash or cash equivalent | TUKYSA Drug, ONCOLOGY | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJE | 2025 |
| 2025-01-07 | PFIZER INC. | $1,027 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Antioch, CA, county Contra Costa County, CA, state California; placed by its city name.
| Measure | Place (city or town) Antioch, CA | County Contra Costa County, CA | State California |
|---|---|---|---|
| Population B01003 | 116,477 | 1,165,012 | 39,287,377 |
| Population, 2020 census P1 | 115,291 | 1,165,927 | 39,538,223 |
| Median age B01002 | 38.4 | 40.5 | 37.9 |
| Under 18 B01001 | 22.8% | 22.0% | 22.0% |
| 65 and over B01001 | 14.3% | 17.1% | 15.7% |
| Households B11001 | 37,381 | 414,417 | 13,548,091 |
| Foreign born B05002 | 24.6% | 26.6% | 27.0% |
| Median household income B19013 | $97,465 | $127,229 | $99,122 |
| Median family income B19113 | $109,115 | $148,679 | $113,346 |
| Per capita income B19301 | $41,008 | $62,927 | $49,513 |
| Poverty rate B17001 | 11.4% | 8.4% | 12.0% |
| Unemployment rate B23025 | 7.4% | 6.5% | 6.6% |
| Civilian labor force B23025 | 60,709 | 608,620 | 20,068,466 |
| Mean commute (minutes) B08013 | 42.0 | 35.3 | 28.7 |
| Bachelor's degree or higher B15003 | 23.9% | 45.2% | 37.1% |
| Housing units B25001 | 38,629 | 429,260 | 14,644,735 |
| Owner-occupied B25003 | 63.6% | 68.0% | 55.9% |
| Renters B25003 | 36.4% | 32.0% | 44.1% |
| Median home value B25077 | $629,700 | $866,800 | $734,700 |
| Median gross rent B25064 | $2,278 | $2,375 | $2,036 |
| White, not Hispanic B03002 | 23.4% | 38.1% | 33.8% |
| Black B03002 | 18.2% | 7.9% | 5.2% |
| Hispanic or Latino B03002 | 35.6% | 27.6% | 40.2% |
| Asian B03002 | 13.9% | 18.6% | 15.3% |
| American Indian and Alaska Native B03002 | 0.5% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Antioch, CA.
Comments